Vanda Pharmaceuticals (VNDA) 10-K2020 FY Annual report

Filed: 11 Feb 21, 7:04am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absorption, acid, advice, allergic, amino, andDirector, ASD, assumption, attached, attendant, autism, boat, briefly, brochure, campaign, Caplyta, capsule, caregiver, charitable, cohort, compliant, confidence, content, context, death, deferral, developmental, diabetic, disagreement, disbarment, dispersed, disregard, dissemination, distancing, distinguish, dopaminergic, ethically, excretion, extract, FCA, GCP, geographically, guide, heading, HHS, Ia, Ib, idiopathic, incidence, Indivior, inherited, insert, involuntary, IRB, irreversible, Kevin, larger, lend, lifted, line, living, LQTM, lung, Moran, morbidity, mortality, nanomolar, neurodegenerative, neuroinflammatory, neuropeptide, nigra, noncompliance, ODYSSEY, outbreak, overcoming, overseen, pandemic, Parkinson, PDP, permission, pneumonia, predominately, preliminarily, promotionally, prosecretory, rapidly, rarity, reaction, recoup, recovery, respiratory, resumed, sacrifice, seizure, signature, Similarly, spectrum, spread, staffing, StatesEurope, StatesIsrael, statutorily, subdivide, substantia, surrogate, tear, tolerance, tract, trip, undergo, undertaken, unexpected, ushering, Variation, ventilation, verify, viral, vitro, vivo, whistleblower, write, writing

Removed: cancelable, caption, clarification, classification, closely, controlled, declaratory, demonstrably, dual, escalate, fit, fundamental, Gian, ineffective, insured, Kelly, negotiate, noncancellable, opening, passing, pattern, petition, Piero, presidential, procedural, Ratification, rehearing, remeasurement, reveal, Reverberi, Senior, societal, sourced, subjecting, substitution, TCJA, Treasurer, twelve, unacceptably, uneconomical, unsafe, Vice, virtually, voluntary

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VNDA transcripts

VNDA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Vanda Pharmaceuticals Inc., (the “Company”), does hereby certify, to the best of such officer’s knowledge, that:

The Annual Report on Form 10-K for the year ended December 31, 2020 (the Form 10-K) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.


February 11, 2021						/s/ Mihael H. Polymeropoulos, M.D.
						Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer (Principal Executive Officer)

February 11, 2021						/s/ Kevin Moran
						Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification “accompanies” the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.